Literature DB >> 954822

A study of muscarinic receptor heterogeneity with weak antagonists.

A Fisher, Y Grunfeld, M Weinstock, S Gitter, S Cohen.   

Abstract

A study of heterogeneity among muscarinic receptors was carried out with new rigid molecules, comprising structures in the fused quinuclidine-valerolactone, quinuclidine-cyclohexenone, quinuclidine-cyclohexanone and quinuclidine-cyclohexane derivatives. These are structurally related to the potent muscarinic agent, 3-acetoxyquinuclidine but substantially different from in it conformation. All proved to antagonize acetylcholine-like activity, but to a different extent in different systems. The equipotent molar ratio with respect to atropine (as 1) was: isolated guinea pig ileum, 10,000-1,000; salivary gland (mouse), 1,000-100; superior cervical ganglion (cat), 100-10; CNS (mouse), approximately 10. It is suggested that the rigid structure induces a three-point constrained fit in the receptor (onium group, hydrophobic moiety and carbonyl group), but that not all muscarinic receptors are capable of responding equally. In this case, receptor specificity of the drug is a direct consequence of its graded departure from the preferred conformation of acetycholine and, therefore, is necessarily associated with partial loss of potency.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954822     DOI: 10.1016/0014-2999(76)90209-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Offset rate of action of muscarinic antagonists depends on their structural flexibility.

Authors:  Y Lass; S Akselrod; B Gavish; S Cohen; A Fisher
Journal:  Experientia       Date:  1979-05-15

2.  Enthalpy-entropy relationship in drug-cholinoceptor interaction: a new approach.

Authors:  S Cohen; F Haberman
Journal:  Br J Pharmacol       Date:  1985-08       Impact factor: 8.739

3.  Comparison of the antimuscarinic activity of mianserin and amitriptyline in the cat superior cervical ganglion.

Authors:  Y H Kwok; F Mitchelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-04       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.